Professor Vincent Segers

Vincent obtained his MD (2002) and PhD (2008) from the University of Antwerp. For his PhD, he studied cardiac regeneration. From 2005–2008, he was a postdoctoral fellow at the lab of Richard Lee (Harvard Medical School, Boston), where he studied myocyte renewal using a genetic fate-mapping approach (published in Nat Med), and where he invented new protease-resistant variants of Stromal cell-derived factor-1 (SDF1). Based on these, Drs. Lee and Segers founded a start-up biotechnology company, called Provasculon, in Cambridge MA, in 2008. There, he managed activities as Senior Director from 2008‒2010. Vincent completed his cardiology training and training in interventional cardiology in 2015. He divides his time between interventional cardiology at the University Hospital of Antwerp and basic research in cardiology at the University of Antwerp. Vincent is primarily interested in intercellular signaling, myocardial function, endothelial cells, fibrosis, and cardiac remodeling.